Novo Nordisk Sees First-Half U.S. Launch of Tresiba

Jan. 31 (Bloomberg) -- Jesper Brandgaard, chief financial officer of Novo Nordisk A/S, discusses the company's fourth-quarter profit reported today, growth expectations for the insulin market and the outlook for U.S. approval of its Tresiba diabetes treatment. He speaks from Copenhagen with Francine Lacqua on Bloomberg Television's "The Pulse." (Source: Bloomberg)
Navy: No Sign of Shooting
51:39 - Bloomberg's Olivia Sterns reports on today's top news stories. (Source: Bloomberg)
  • `Yes` or `No`: What Is Greece Really Voting For?
  • How Carlister Brings a Used Car Lot to Your Phone
  • Foxx: Short-Term Cycles for Highway Trust Fund Must End